PhD Defense: Translational Bladder Cancer Research
From disease discovery to personalized therapy stratification with patient-derived organoids, Viergever (Faculteit Medische Wetenschappen / LAB) presents a study on bladder cancer.
Bladder cancer is a common form of cancer, with over 610,000 new cases worldwide in 2022, primarily affecting men, making it the sixth most common cancer in men. The primary risk factor is smoking, and a common symptom is painless blood in the urine.
Bladder cancer can be divided into different types, including non-muscle-invasive, muscle-invasive, and metastatic bladder cancer. Chemotherapy and immunotherapy are commonly used treatments, but not all patients respond equally well due to the genetic complexity and rapid mutation of the disease.
This research explores new methods to study and treat bladder cancer using organoids, small 3D models of tumours that resemble the original tumour, to better understand how tumours respond to treatments.
No direct quote available in the given text.
Author's summary: Research on bladder cancer using patient-derived organoids for personalized therapy.
More News
- Man arrested for firearm and narcotics possesion at traffic stop | News Channel 3-12
- PhD Defense: Translational bladder cancer research From disease discovery to personalized therapy stratification with patient-derived organoids
- On first International Day of the Deep Seabed, we seek stewardship and consensus (commentary)